Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence
meet DSM-IV criteria for opiate dependence, and no other active substance dependence disorder save nicotine dependence
clinically stable, and low risk for suicide as determined by principal investigator and screening questionnaire
abstinent from non-prescribed opiate use for at least two weeks from Baseline 1 and free from opiate withdrawal symptoms. If on agonist therapy, dose must be stable for 2 weeks before study visit.
must be able to use nasal spray
negative salivary drug screen, save for opiates
You may not be if
any active medical condition that in the opinion of the investigator will interfere with the objectives of the study
any active, severe mental illness, neurological disorder, including schizophrenia, autism, Asperger's syndrome
are unsuitable in any way to participate in this study, in the opinion of the investigator
hospitalizations due to complications of an Axis 1 disorder for the past 12 months, excluding drug or alcohol rehabilitation
any clinically significant chronic pain condition, as determined by the principal investigator
positive salivary drug screen at the time of the visit, for any substance other than opiates or another prescribed medication
Clareo Health | Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence
